Maria Elisa Borroni

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Richard J. Gralla, Snežana Bošnjak, A. Hontsa et al. · Annals of Oncology · 2014 · 190 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Matti Aapro, Meinolf Karthaus, Lee S. Schwartzberg et al. · Supportive Care in Cancer · 2016 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)

Meinolf Karthaus, Tibor Csőszi, Vito Lorusso et al. · Supportive Care in Cancer · 2015 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies

Lee S. Schwartzberg, Meinolf Karthaus, Giorgia Rossi et al. · Cancer Medicine · 2019 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17